Division of Sanofi
Latest From Sanofi Pasteur
Dengvaxia’s Restrictive Indication Will Make Immunization Recommendations Difficult, ACIP Members Say
The need to screen individuals in dengue-endemic areas for prior infection before administering Sanofi’s vaccine will be difficult to operationalize, particularly in the absence of a reliable and rapid diagnostic, experts say; Advisory Committee on Immunization Practices working group aims for full committee vote on use recommendations in February 2020.
Vaccine specialist Hilleman announces partnership with another Indian firm, Bharat Biotech, to develop, manufacture and commercialize its simpler and cheaper oral cholera vaccine.
Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.
Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.
- Therapeutic Areas
- Infectious & Viral Diseases
- Aventis Pasteur
- Aventis Pasteur Inc.
- Western Europe
- Parent & Subsidiaries
- Senior Management
David Loew, EVP, Head
John Shiver, SVP, R&D
- Contact Info
Phone: (33) 4 37 37 01 00
14 Epsace Henry Vallee
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.